Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Extravascular Factor IX Pool Fed By Prophylaxis Is a True Hemostatic Barrier Against Bleeding

Alexandre Leuci, Nathalie Enjolras, Muriel Marano, Melanie Daniel, Marie Brevet, Philippe Connes, Yesim G. Dargaud

Blood (2023) 142 (Supplement 1): 5462.

https://doi.org/10.1182/blood-2023-179522

Published: 2023

Journal Articles

Multicenter Evaluation of the Hemostatic Activity of Emicizumab in Patients with Severe Hemophilia a Using Thrombin Generation Assay

Laurie Josset, Maissaa Janbain, Annaelle De Wreede, Christophe Nougier, Stephanie Desage, Anne Lienhart, Xavier Delavenne, Yesim G. Dargaud

Blood (2023) 142 (Supplement 1): 5459.

https://doi.org/10.1182/blood-2023-179551

Published: 2023

Journal Articles

Stromal Cell-Derived Factor 1 Alpha (SDF-1α), Cartilage Oligomeric Matrix Protein (COMP) and Circulating microRNAs 208a-3p and 221-3p: Potential Signature Biomarkers of Hemophilic Arthropathy

Alexandre Leuci, Melanie Robert, Laurie Josset, Muriel Marano, Philippe Connes, Stephanie Desage, Sandrine Meunier, Anne Lienhart, Yesim G. Dargaud

Blood (2023) 142 (Supplement 1): 5467.

https://doi.org/10.1182/blood-2023-179574

Published: 2023

Journal Articles

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Yesim G. Dargaud, MDPhD, Robert Klamroth, Luminita Rusen, MD, Jerzy Windyga, MD, Johann Bichler, PhD, Sigurd Knaub, Claude Negrier, MD

Blood (2016) 128 (22): 1410.

https://doi.org/10.1182/blood.V128.22.1410.1410

Published: 2016

Journal Articles

Effect of Five Therapeutic Strategies on the Coagulation Defect Induced By the Thrombomodulin C.1611C>a Mutation

Yesim G. Dargaud, MDPhD, Yohann Jourdy, Sandra Le Quellec, Coen Hemker, Theo Lindhout, Elisabetta Castoldi, Claude Negrier, MD

Blood (2015) 126 (23): 2287.

https://doi.org/10.1182/blood.V126.23.2287.2287

Published: 2015

Journal Articles

Individually Tailored Prophylaxis Using a Risk Score for the Management of Pregnant Women with Increased Risk of Venous Thromboembolism

Yesim G. Dargaud, MDPhD, Lucia Rugeri, Chloe Fleury, Helene Desmurs Clavel, Jacques Ninet, Catherine Battie, Pascal Gaucherand, Cyril Huissoud, Rene Charles Rudigoz, Christine Trzeciak

Blood (2015) 126 (23): 889.

https://doi.org/10.1182/blood.V126.23.889.889

Published: 2015

Journal Articles

The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?

Yesim G. Dargaud, MDPhD, Marc Fouassier, MD, Sophie Ducastelle, MD, Philippe Moreau, MD, Charles Dumontet, MD PhD, Mauricette Michallet, MD PhD, Jean-Claude Bordet, Claude Negrier, MD PhD

Blood (2014) 124 (21): 2037.

https://doi.org/10.1182/blood.V124.21.2037.2037

Published: 2014

NARROW

Extravascular Factor IX Pool Fed By Prophylaxis Is a True Hemostatic Barrier Against Bleeding

Multicenter Evaluation of the Hemostatic Activity of Emicizumab in Patients with Severe Hemophilia a Using Thrombin Generation Assay

Stromal Cell-Derived Factor 1 Alpha (SDF-1α), Cartilage Oligomeric Matrix Protein (COMP) and Circulating microRNAs 208a-3p and 221-3p: Potential Signature Biomarkers of Hemophilic Arthropathy

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Effect of Five Therapeutic Strategies on the Coagulation Defect Induced By the Thrombomodulin C.1611C>a Mutation

Individually Tailored Prophylaxis Using a Risk Score for the Management of Pregnant Women with Increased Risk of Venous Thromboembolism

The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?

Email alerts

ASH Publications

American Society of Hematology

Extravascular Factor IX Pool Fed By Prophylaxis Is a True Hemostatic Barrier Against Bleeding

Multicenter Evaluation of the Hemostatic Activity of Emicizumab in Patients with Severe Hemophilia a Using Thrombin Generation Assay

Stromal Cell-Derived Factor 1 Alpha (SDF-1α), Cartilage Oligomeric Matrix Protein (COMP) and Circulating microRNAs 208a-3p and 221-3p: Potential Signature Biomarkers of Hemophilic Arthropathy

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Effect of Five Therapeutic Strategies on the Coagulation Defect Induced By the Thrombomodulin C.1611C>a Mutation

Individually Tailored Prophylaxis Using a Risk Score for the Management of Pregnant Women with Increased Risk of Venous Thromboembolism

The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only